Hypercalcemia (Hypercalcemic Crisis) — Management Pathway

Step-by-step decision

Choose step by step as prompted; reaching an endpoint gives the management recommendation. You can go back a step or restart anytime.

🎓 Want to practice? Do a case challenge with this pathway → (get a case, choose management step by step, scored).

Full pathway

1. [Decision] Calcium severity
   Corrected calcium level and symptoms? (Corrected calcium: mild <3.0 mmol/L (12 mg/dL), moderate 3.0–3.5, severe >3.5 mmol/L (14 mg/dL). Symptoms: polyuria, dehydration, fatigue, altered mentation, arrhythmia. Principle: restore volume before giving a bisphosphonate.)
   • Severe (>3.5) or symptomatic → Severe / symptomatic
   • Mild–moderate and asymptomatic → Mild–moderate, asymptomatic
2. [End] Mild–moderate, asymptomatic
   Treat the underlying cause (hyperparathyroidism, malignancy, etc.), avoid precipitants (thiazides, prolonged immobilization, high calcium/vitamin D intake), modest hydration, follow up and monitor; most need no acute calcium-lowering therapy.
3. [End] Severe / symptomatic
   1) Aggressive 0.9% sodium chloride volume expansion (correct dehydration, promote calciuresis, target urine output ≥100 mL/h) as the foundation. 2) Calcitonin (rapid onset over hours; tachyphylaxis at 48–72 h) as a bridge. 3) IV bisphosphonate (zoledronic acid 4 mg over ≥15 min, preferred; onset 2–4 days; caution/reduce in renal impairment, relative contraindication if CrCl <30). 4) Refractory/renal injury → denosumab; vitamin-D-mediated (granulomatous/lymphoma) → glucocorticoid; refractory severe disease or renal failure → dialysis. Consider a loop diuretic only after volume is restored and only for volume overload/cardiorenal impairment. Treat the underlying cause.

Source guidelines & references

• Endocrine Society 2023 Guideline on the treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab 2023

This pathway is our own synthesis of the decision logic in the guidelines above (not the guideline verbatim); thresholds and workflows change as guidelines update — in practice follow the latest guideline, your institution's protocol and the individual patient.

Other pathways